What is the recommended treatment and dosage for Mirtazapine (an antidepressant) in patients with major depressive disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mirtazapine for Major Depressive Disorder

Recommended Dosage

Start mirtazapine at 15 mg once daily, preferably in the evening before sleep, and increase up to a maximum of 45 mg daily if needed, with dose changes made no more frequently than every 1-2 weeks. 1

Dosing Algorithm

  • Initial dose: 15 mg once daily at bedtime 1
  • Dose titration: If inadequate response after 6-8 weeks, increase dose up to maximum 45 mg daily 2, 1
  • Timing of dose changes: Wait at least 1-2 weeks between adjustments to allow adequate evaluation of response 1
  • Effective range: 15-45 mg daily 3, 1, 4

Monitoring Timeline

Begin assessing therapeutic response and adverse effects within 1-2 weeks of starting treatment, with particular attention to suicidal ideation during this early period. 3, 2

  • Week 1-2: Initial assessment for early response (sleep and anxiety symptoms may improve first), monitor for suicidal thoughts, agitation, or unusual behavioral changes 3, 2, 5
  • Week 6-8: If inadequate response by this point, modify treatment 3, 2
  • Week 2-4: Full antidepressant effect typically achieved 5, 4

Duration of Treatment

Continue mirtazapine for 4-9 months after achieving satisfactory response in first-episode depression; patients with 2 or more prior episodes require longer maintenance therapy. 3, 2

  • First episode: 4-9 months continuation after remission 3, 2
  • Recurrent depression (≥2 episodes): Extended maintenance therapy beyond 9 months 3, 2
  • Discontinuation: Taper gradually rather than stopping abruptly to minimize withdrawal symptoms 1

Clinical Advantages

Mirtazapine is particularly suitable for patients with depression accompanied by insomnia, anxiety, anorexia, or weight loss due to its sedating properties and appetite-stimulating effects. 2

  • Faster onset: More rapid action than fluoxetine, paroxetine, and sertraline for some symptoms 2
  • Sleep benefits: Improves sleep disturbances within the first week, before full antidepressant effect 2, 5
  • Appetite stimulation: Promotes weight gain, making it ideal for depressed patients with anorexia 2
  • Preferred agent: Considered a first-line option alongside SSRIs and SNRIs due to favorable adverse effect profile 3

Common Adverse Effects to Monitor

  • Most common: Somnolence/sedation, increased appetite, weight gain 2, 1, 4
  • Other effects: Dry mouth, constipation or diarrhea, dizziness 3, 2, 4
  • Less common than SSRIs: Minimal sexual dysfunction, gastrointestinal symptoms, or insomnia compared to SSRIs 5
  • Cardiovascular: Minimal cardiovascular and anticholinergic effects 5

Important Dosage Modifications

Reduce mirtazapine dose when co-administered with strong CYP3A4 inhibitors (ketoconazole, clarithromycin) or cimetidine; increase dose with strong CYP3A inducers (carbamazepine, phenytoin, rifampin). 1

Critical Safety Considerations

  • Screen for bipolar disorder: Assess personal and family history before initiating treatment 1
  • MAOI interactions: Allow 14 days between discontinuing an MAOI and starting mirtazapine, and vice versa 1
  • Suicide risk: Highest during first 1-2 months of treatment; monitor closely for worsening depression, agitation, or suicidal thoughts 3

When to Modify Treatment

If no adequate response within 6-8 weeks at appropriate doses, switch to an SSRI or SNRI, or add another antidepressant with a different mechanism of action. 3, 2

References

Guideline

Mirtazapine Treatment Guidelines for Major Depressive Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.